vadimezan has been researched along with Carcinoma, Lewis Lung in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albelda, SM; Cheng, G; Fridlender, ZG; Jassar, A; Kapoor, V; Levy, L; Mishalian, I; Singhal, S; Sun, J; Wang, LC | 1 |
| Cao, N; Du, G; Duan, Y; Guo, Z; Han, G; Li, G; Li, H; Lin, H; Liu, L; Ma, X | 1 |
| Hu, Y; Li, Y; Lou, L; Quan, H; Wu, Q; Xu, Y | 1 |
| Albelda, SM; Burdick, MD; Cheung, L; Ching, LM; Jassar, AS; Kaiser, LR; Kapoor, V; Silverberg, MB; Strieter, RM; Sun, J; Suzuki, E | 1 |
| Ching, LM; Hermans, IF; Matthews, KE; Roberts, JM; Ronchese, F | 1 |
| Ching, LM; Roberts, ZJ; Vogel, SN | 1 |
6 other study(ies) available for vadimezan and Carcinoma, Lewis Lung
| Article | Year |
|---|---|
Using macrophage activation to augment immunotherapy of established tumours.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Immunotherapy; Lung Neoplasms; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells; Neutrophils; Tumor Microenvironment; Xanthones | 2013 |
Tumor interstitial fluid promotes malignant phenotypes of lung cancer independently of angiogenesis.
Topics: Animals; Apoptosis; Aquaporin 1; Autophagy; Carcinoma, Lewis Lung; Cell Movement; Cell Proliferation; Disease Progression; Epithelial-Mesenchymal Transition; Extracellular Fluid; Female; Humans; Hydroxyindoleacetic Acid; Inflammation; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Neovascularization, Pathologic; Phenotype; Platelet Endothelial Cell Adhesion Molecule-1; Wound Healing; Xanthones | 2015 |
p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Lewis Lung; Female; Human Umbilical Vein Endothelial Cells; Humans; Injections, Intraperitoneal; Macrophages; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; RNA Interference; Tumor Necrosis Factor-alpha; Xanthones | 2012 |
Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemokines; Cytokines; Disease Models, Animal; Immunotherapy; Lung Neoplasms; Macrophages; Membrane Glycoproteins; Mesothelioma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neovascularization, Pathologic; Perforin; Pore Forming Cytotoxic Proteins; Xanthones | 2005 |
5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dendritic Cells; Drug Synergism; Female; Immunotherapy, Adoptive; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Xanthones | 2006 |
IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antineoplastic Agents; Blood Vessels; Carcinoma, Lewis Lung; Chemokine CXCL10; Female; Interferon-beta; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Xanthones | 2008 |